Itau Unibanco Holding S.A. Sells 111 Shares of Illumina, Inc. (NASDAQ:ILMN)

Itau Unibanco Holding S.A. cut its stake in Illumina, Inc. (NASDAQ:ILMN) by 19.0% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 473 shares of the life sciences company’s stock after selling 111 shares during the period. Itau Unibanco Holding S.A.’s holdings in Illumina were worth $62,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. Industrial Alliance Investment Management Inc. bought a new stake in Illumina during the second quarter worth about $34,000. Massmutual Trust Co. FSB ADV lifted its holdings in shares of Illumina by 65.1% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock worth $56,000 after acquiring an additional 168 shares during the period. Private Trust Co. NA boosted its position in shares of Illumina by 81.2% during the 3rd quarter. Private Trust Co. NA now owns 473 shares of the life sciences company’s stock worth $62,000 after acquiring an additional 212 shares in the last quarter. Mizuho Securities Co. Ltd. bought a new position in Illumina in the second quarter valued at approximately $63,000. Finally, Focused Wealth Management Inc bought a new position in Illumina in the third quarter valued at approximately $63,000. 89.42% of the stock is currently owned by institutional investors.

Illumina Stock Performance

NASDAQ:ILMN opened at $140.60 on Wednesday. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.85 and a current ratio of 2.43. Illumina, Inc. has a fifty-two week low of $100.08 and a fifty-two week high of $156.66. The company has a 50 day simple moving average of $142.42 and a two-hundred day simple moving average of $126.45. The company has a market capitalization of $22.30 billion, a PE ratio of -14.12 and a beta of 1.11.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.26. The company had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.08 billion. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. Illumina’s revenue for the quarter was down 3.5% compared to the same quarter last year. During the same period in the prior year, the company posted $0.33 earnings per share. Research analysts anticipate that Illumina, Inc. will post 4.11 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. TD Cowen raised their target price on Illumina from $166.00 to $177.00 and gave the company a “buy” rating in a report on Tuesday, November 5th. Canaccord Genuity Group raised their price objective on Illumina from $130.00 to $145.00 and gave the company a “hold” rating in a research note on Tuesday, November 5th. UBS Group lifted their target price on Illumina from $133.00 to $145.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Leerink Partners increased their target price on shares of Illumina from $160.00 to $200.00 and gave the stock an “outperform” rating in a report on Thursday, October 17th. Finally, Royal Bank of Canada lifted their price target on shares of Illumina from $252.00 to $254.00 and gave the company an “outperform” rating in a report on Tuesday, November 5th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, fourteen have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, Illumina has a consensus rating of “Moderate Buy” and an average price target of $164.00.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.